Flanigan RC - Search Results

1

Estimating the impact of new clinical trial proven cancer therapy and cancer chemoprevention on population mortality: the Karnofsky Memorial lecture.

Unger JM, LeBlanc M, Crowley JJ, Grossman HB, Natale RB, Wozniak AJ, Berenson JR, List AF, Peters WA 3rd, Flanigan RC, Macdonald JS, Al-Sarraf M, Thompson IM, Coltman CA Jr. Unger JM, et al. Among authors: flanigan rc. J Clin Oncol. 2003 Dec 1;21(23 Suppl):246s-252s. doi: 10.1200/JCO.2003.08.512. J Clin Oncol. 2003. PMID: 14645404

2

Evaluation of low dose alpha-interferon (Roferon-A) in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.

Marshall ME, Wolf M, Crawford ED, Thompson IM, Flanigan R, Balcerzak SP, Meyers FJ. Marshall ME, et al. Cancer Biother. 1995 Fall;10(3):205-9. doi: 10.1089/cbr.1995.10.205. Cancer Biother. 1995. PMID: 8547959 Clinical Trial.

3

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Flanigan RC, et al. J Urol. 2004 Mar;171(3):1071-6. doi: 10.1097/01.ju.0000110610.61545.ae. J Urol. 2004. PMID: 14767273 Free article. Clinical Trial.

4

Is a 1-CM margin necessary during nephron-sparing surgery for renal cell carcinoma?

Piper NY, Bishoff JT, Magee C, Haffron JM, Flanigan RC, Mintiens A, Van Poppel HP, Thompson IM, Harmon WJ. Piper NY, et al. Among authors: flanigan rc. Urology. 2001 Dec;58(6):849-52. doi: 10.1016/s0090-4295(01)01393-0. Urology. 2001. PMID: 11744443

5

Oral bropirimine immunotherapy of carcinoma in situ of the bladder: results of a phase II trial.

Sarosdy MF, Lowe BA, Schellhammer PF, Lamm DL, Graham SD Jr, Grossman HB, See WA, Peabody JO, Moon TD, Flanigan RC, Crawford ED, Morganroth J. Sarosdy MF, et al. Among authors: flanigan rc. Urology. 1996 Jul;48(1):21-7. doi: 10.1016/s0090-4295(96)90059-x. Urology. 1996. PMID: 8693646 Clinical Trial.

6

The role of cytoreductive nephrectomy in the era of molecular targeted therapy.

Polcari AJ, Gorbonos A, Milner JE, Flanigan RC. Polcari AJ, et al. Among authors: flanigan rc. Int J Urol. 2009 Mar;16(3):227-33. doi: 10.1111/j.1442-2042.2008.02245.x. Epub 2009 Feb 4. Int J Urol. 2009. PMID: 19207114 Review.

7

A primer on clinical trial design.

Ellimoottil C, Vijan S, Flanigan RC. Ellimoottil C, et al. Among authors: flanigan rc. Urol Oncol. 2015 Mar;33(3):116-21. doi: 10.1016/j.urolonc.2014.12.014. Epub 2015 Jan 23. Urol Oncol. 2015. PMID: 25624092 Review.

8

Phase II trial of echinomycin for the treatment of advanced renal cell carcinoma. A Southwest Oncology Group study.

Marshall ME, Wolf MK, Crawford ED, Taylor S, Blumenstein B, Flanigan R, Meyers FJ, Hynes HE, Barlogie B, Eisenberger M. Marshall ME, et al. Invest New Drugs. 1993 May-Aug;11(2-3):207-9. doi: 10.1007/BF00874157. Invest New Drugs. 1993. PMID: 8262733 Clinical Trial.

9

Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study.

Kish JA, Wolf M, Crawford ED, Leimert JT, Bueschen A, Neefe JR, Flanigan RC. Kish JA, et al. Among authors: flanigan rc. Cancer. 1994 Aug 1;74(3):916-9. doi: 10.1002/1097-0142(19940801)74:3<916::aid-cncr2820740319>3.0.co;2-z. Cancer. 1994. PMID: 8039119 Clinical Trial.

10

A phase II trial of interferon-alpha and 5-fluorouracil in patients with advanced renal cell carcinoma. A Southwest Oncology Group study.

Elias L, Blumenstein BA, Kish J, Flanigan RC, Wade JL, Lowe BA, Goodwin JW, Crawford ED. Elias L, et al. Among authors: flanigan rc. Cancer. 1996 Sep 1;78(5):1085-8. doi: 10.1002/(SICI)1097-0142(19960901)78:5<1085::AID-CNCR19>3.0.CO;2-Z. Cancer. 1996. PMID: 8780547 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

229 results

Search Page